Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKinsey
Colorcon
Medtronic
McKesson

Last Updated: October 1, 2022

BAQSIMI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Baqsimi patents expire, and when can generic versions of Baqsimi launch?

Baqsimi is a drug marketed by Eli Lilly And Co and is included in one NDA. There are four patents protecting this drug.

This drug has eighty-two patent family members in forty countries.

The generic ingredient in BAQSIMI is glucagon. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the glucagon profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Baqsimi

A generic version of BAQSIMI was approved as glucagon by LILLY on September 11th, 1998.

  Try it Free

Summary for BAQSIMI
International Patents:82
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 2
Formulation / Manufacturing:see details
Drug Prices: Drug price information for BAQSIMI
What excipients (inactive ingredients) are in BAQSIMI?BAQSIMI excipients list
DailyMed Link:BAQSIMI at DailyMed
Drug patent expirations by year for BAQSIMI
Drug Prices for BAQSIMI

See drug prices for BAQSIMI

Recent Clinical Trials for BAQSIMI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eli Lilly and CompanyPhase 1
Azienda Ospedaliera Città della Salute e della Scienza di TorinoPhase 4

See all BAQSIMI clinical trials

US Patents and Regulatory Information for BAQSIMI

BAQSIMI is protected by four US patents and one FDA Regulatory Exclusivity.

Patents protecting BAQSIMI

Nasal powder formulation for treatment of hypoglycemia
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES

Medication delivery systems and methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Device for dispensing a fluid product
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Fluid or powdery product dispensing device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting BAQSIMI

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for BAQSIMI

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Tetris Pharma B.V Ogluo glucagon EMEA/H/C/005391
Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.,
Authorised no no no 2021-02-11
Eli Lilly Nederland B.V. Baqsimi glucagon EMEA/H/C/003848
Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Authorised no no no 2019-12-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for BAQSIMI

See the table below for patents covering BAQSIMI around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1339501 DISPOSITIF DE DISTRIBUTION DE PRODUIT FLUIDE OU PULVERULENT (FLUID OR POWDERY PRODUCT DISPENSING DEVICE) See Plans and Pricing
Japan 3940079 See Plans and Pricing
China 1494461 See Plans and Pricing
South Korea 20170103934 저혈당증의 치료를 위한 비강 분말 제제 See Plans and Pricing
Chile 2017002031 Formulación en polvo nasal para el tratamiento de hipoglicemia See Plans and Pricing
Costa Rica 20170373 FORMULACIÓN EN POLVO NASAL PARA EL TRATAMIENTO DE HIPOGLIGEMIA See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
AstraZeneca
McKinsey
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.